Select: All | None

Select: All | None

Select: All | None

METHOD

IMPERIAL INNOVATIONS, McGill University, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, SWANSEA UNIVERSITY, Université du Québec à Chicoutimi

A method of identifying a subject falling within a new patient population characterised by eosinophil IgE mediated allergic inflammation, involving analysing the level of methylation in a DNA sample obtained from the subject for one or more promoter regions associated with one or more genes. Individuals within this new patient population are expected to be likely to respond to therapies for eosinophil IgE mediated inflammation, such as inhibitors of IL-5, IL-13, IgE or M1 prime activity and...

PROGNOSTIC GENE EXPRESSION SIGNATURE FOR SQUAMOUS CELL CARCINOMA OF THE LUNG

University Health Network

Provided is a gene expression signature consisting of 12 biomarkers for use in prognosing or classifying a subject with lung squamous cell carcinoma into a poor survival group or a good survival group. The 12-gene signature specific for squamous cell carcinoma consists of the biomarkers RPL22, VEGFA, G0S2, NES, TNFRSF25, DKFZP586P0123, COL8A2, ZNF3, PJPK5, RNFT2, ARHGEF12 and PTPN20A.

ENDONUCLEASE FOR GENOME EDITING

Western University

A chimeric endonuclease is provided comprising the GIY-YIG nuclease domain which is linked to a DNA-targeting domain by a linking domain. The endonuclease is useful in gene editing.

MECP2E1 GENE

Centre for Addiction and Mental Health, Hospital for Sick Children

The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatri c disorders or development disorders.

NOVEL REGULATORS OF INNATE IMMUNITY AND USES THEREOF

University of Montreal

Novel genes and pathways associated with the regulation of innate immunity, more particularly of Type I and Type III interferon (IFN) production in response to viral infection. Methods for modulating innate immunity and Type I/Type III IFN production, and for the identification of modulators of innate immunity and Type I/Type III IFN production, are described.

GROWTH DIFFERENTIATION FACTOR 15 AS BIOMARKER FOR METFORMIN

McMaster University, MC MASTER UNIVERSITY, SANOFI-AVENTIS DEUTSCHLAND GMBH

The present invention relates to metformin for use in treating a patient, wherein the patient exhibits an increased level of GDF15 in response to metformin treatment; to methods of identifying a patient who will benefit or who will not benefit from metformin treatment; methods of treating a patient at risk of developing or suffering from a disease or disorder comprising administering therapeutically effective amount of metformin; methods of adapting the dosage of metformin; the usage of...

COMPOUNDS AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS AND/OR HEMATOPOIETIC PROGENITOR CELLS

UNIVERSITE DE MONTREAL, University of Montreal

Compounds of general formula or salts or prodrugs thereof, are provided and described herein. The compounds are useful to expand hematopoietic stem cell and/or hematopoietic progenitor cell populations. Particularly, the hematopoietic cells are human cells. The compounds are also useful in the medical treatment of hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immune-deficient disease in a subject.